ZA200805511B - Levodopa prodrug mesylate, compositions thereof, and uses thereof - Google Patents

Levodopa prodrug mesylate, compositions thereof, and uses thereof

Info

Publication number
ZA200805511B
ZA200805511B ZA200805511A ZA200805511A ZA200805511B ZA 200805511 B ZA200805511 B ZA 200805511B ZA 200805511 A ZA200805511 A ZA 200805511A ZA 200805511 A ZA200805511 A ZA 200805511A ZA 200805511 B ZA200805511 B ZA 200805511B
Authority
ZA
South Africa
Prior art keywords
compositions
levodopa prodrug
prodrug mesylate
mesylate
levodopa
Prior art date
Application number
ZA200805511A
Other languages
English (en)
Inventor
Jia-Ning Xiang
Xuedong Dai
Cindy X Li Jianhua Zhou
Mark Q Nguyen
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of ZA200805511B publication Critical patent/ZA200805511B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
ZA200805511A 2005-12-05 2006-12-04 Levodopa prodrug mesylate, compositions thereof, and uses thereof ZA200805511B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74187605P 2005-12-05 2005-12-05

Publications (1)

Publication Number Publication Date
ZA200805511B true ZA200805511B (en) 2010-02-24

Family

ID=38123406

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805511A ZA200805511B (en) 2005-12-05 2006-12-04 Levodopa prodrug mesylate, compositions thereof, and uses thereof

Country Status (20)

Country Link
US (5) US7563821B2 (fr)
EP (1) EP1959948B1 (fr)
JP (1) JP5153641B2 (fr)
KR (1) KR101396639B1 (fr)
CN (1) CN101365439B (fr)
AU (1) AU2006322051B2 (fr)
BR (1) BRPI0619425A2 (fr)
CA (1) CA2631643C (fr)
CY (1) CY1113108T1 (fr)
DK (1) DK1959948T3 (fr)
ES (1) ES2391575T3 (fr)
IL (1) IL191937A (fr)
NO (1) NO20082768L (fr)
NZ (1) NZ569485A (fr)
PL (1) PL1959948T3 (fr)
PT (1) PT1959948E (fr)
RU (1) RU2429223C2 (fr)
TW (1) TWI403493B (fr)
WO (1) WO2007067495A2 (fr)
ZA (1) ZA200805511B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121070A1 (fr) 2004-06-04 2005-12-22 Xenoport, Inc. Promedicaments de levodopa, et compositions et leurs utilisations
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20080070984A1 (en) * 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
CA2673336A1 (fr) 2006-12-21 2008-06-26 Xenoport, Inc. Promedicaments diesters dimethyle substitues a base de levodopa et procedes d'utilisation
WO2008079387A1 (fr) * 2006-12-21 2008-07-03 Xenoport, Inc. Promédicaments de diester de lévopoda protégés par catechol, compositions et méthodes d'utilisation
WO2010045599A1 (fr) 2008-10-17 2010-04-22 Pharmacofore, Inc. Compositions pharmaceutiques avec libération atténuée d'opioïdes phénoliques
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201040130A (en) 2009-04-17 2010-11-16 Merz Pharma Gmbh & Co Kgaa Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
CN102695545B (zh) 2009-09-08 2016-08-17 特色疗法股份有限公司 包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物
WO2011056240A2 (fr) 2009-11-09 2011-05-12 Xenoport, Inc. Compositions pharmaceutiques et formes galéniques orales d'un promédicament de lévodopa et procédés d'utilisation
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133178A1 (fr) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprenant un promédicament de tapentadol modifié phénol clivable par enzyme
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
CN103228618B (zh) * 2010-12-02 2016-02-17 小野药品工业株式会社 新化合物及其医药用途
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
WO2012122420A2 (fr) 2011-03-09 2012-09-13 Pharmacofore, Inc. Promédicaments opioïdes présentant des groupes de liaison hétérocycliques
WO2013063082A1 (fr) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Compositions de rasagiline implantables et méthodes de traitement associées
US9575244B2 (en) 2013-01-04 2017-02-21 Bal Makund Dhar Light guide apparatus and fabrication method thereof
FR3008411B1 (fr) 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
CN103554078B (zh) * 2013-11-22 2016-03-02 浙江安赛生物科技有限公司 低级醛（c2-c10）丙二醇缩醛的合成方法
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
WO2017177262A1 (fr) 2016-04-11 2017-10-19 University Of Canberra Compositions ophtalmiques comprenant de la lévodopa, un antioxydant et un support aqueux
IL264178B2 (en) 2016-07-14 2024-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
WO2019097120A1 (fr) 2017-11-16 2019-05-23 Orion Corporation Nouvelle utilisation et nouvelles formes posologiques pharmaceutiques
SG11202101817UA (en) 2018-09-13 2021-03-30 Univ Canberra Methods of inhibition
CA3107139C (fr) * 2018-09-21 2023-01-03 Kashiv Biosciences, Llc Compositions a liberation prolongee comprenant du trihexyphenidyle
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
JP2022540922A (ja) * 2019-07-17 2022-09-20 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態
CA3191084A1 (fr) 2020-09-09 2022-03-17 Gerald Burke Formulations d'un modulateur de somatostatine
JP2023541050A (ja) * 2020-09-11 2023-09-27 シンアジャル コーポレイション 連続的な経口薬物送達の方法
IL305493A (en) 2021-03-09 2023-10-01 Ensysce Biosciences Inc Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
CA3230025A1 (fr) 2021-09-29 2023-04-06 Lynn Kirkpatrick Promedicaments de methadone clivables par voie enzymatique et procedes d?utilisation associes
CN116500162A (zh) * 2023-04-27 2023-07-28 北京和合医学诊断技术股份有限公司 一种同时检测6种药物浓度的液相色谱-质谱分析方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4038411A (en) 1973-09-25 1977-07-26 Merck & Co., Inc. Antihypertensive amino acid esters
US3983138A (en) 1973-09-25 1976-09-28 Merck & Co., Inc. Amino acid esters
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
FR2365341A1 (fr) * 1976-09-28 1978-04-21 Synthelabo Derives de l'acide l-(phenyl-3 amino-2 propionyloxy)-2 acetique
US4180509A (en) * 1977-07-01 1979-12-25 Merrell Toraude Et Compagnie α-Ethynyl tryptophanes
US4311706A (en) 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS5824547A (ja) 1981-08-06 1983-02-14 Nippon Zoki Pharmaceut Co Ltd 新規アミノ酸誘導体
US4914222A (en) 1983-08-29 1990-04-03 Merck & Co., Inc. Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process
LU85757A1 (fr) 1985-02-04 1986-09-02 Univ Catholique Louvain Derives nouveaux de la l-dopa,procedes pour leur preparation et compositions pharmaceutiques concernant de tels composes
US4873263A (en) 1985-12-30 1989-10-10 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
JPS62258347A (ja) * 1986-05-02 1987-11-10 Banyu Pharmaceut Co Ltd 無水結晶形態のｌ−スレオ−３−（３，４−ジヒドロキシフエニル）−ｎ−メチルセリン
DE252290T1 (de) 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
JPH07278076A (ja) * 1994-04-12 1995-10-24 Ajinomoto Co Inc Ｌ−フェニルアラニン・モノメチル硫酸塩の晶析方法
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB2348371B (en) 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
WO2002044324A2 (fr) 2000-10-06 2002-06-06 Xenoport, Inc. Composes derives des acides biliaires pouvant ameliorer l'absorption orale et la biodisponibilite systemique de medicaments
US20020151526A1 (en) 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
WO2003041646A2 (fr) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Sels de l-dopa ethylester et leurs utilisations
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
US7101912B2 (en) * 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121070A1 (fr) 2004-06-04 2005-12-22 Xenoport, Inc. Promedicaments de levodopa, et compositions et leurs utilisations
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US20080070984A1 (en) 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
CA2673336A1 (fr) 2006-12-21 2008-06-26 Xenoport, Inc. Promedicaments diesters dimethyle substitues a base de levodopa et procedes d'utilisation
WO2008079387A1 (fr) 2006-12-21 2008-07-03 Xenoport, Inc. Promédicaments de diester de lévopoda protégés par catechol, compositions et méthodes d'utilisation
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2011056240A2 (fr) 2009-11-09 2011-05-12 Xenoport, Inc. Compositions pharmaceutiques et formes galéniques orales d'un promédicament de lévodopa et procédés d'utilisation

Also Published As

Publication number Publication date
NZ569485A (en) 2011-06-30
US20110111062A1 (en) 2011-05-12
CA2631643C (fr) 2015-07-07
PL1959948T3 (pl) 2012-12-31
RU2008127312A (ru) 2010-01-20
WO2007067495A3 (fr) 2007-09-27
BRPI0619425A2 (pt) 2011-10-04
EP1959948B1 (fr) 2012-07-18
US7563821B2 (en) 2009-07-21
AU2006322051B2 (en) 2011-09-29
ES2391575T3 (es) 2012-11-27
US7893105B2 (en) 2011-02-22
WO2007067495A2 (fr) 2007-06-14
DK1959948T3 (da) 2012-08-20
HK1121381A1 (en) 2009-04-24
US20090156679A1 (en) 2009-06-18
RU2429223C2 (ru) 2011-09-20
KR20080073365A (ko) 2008-08-08
CN101365439B (zh) 2012-12-26
CA2631643A1 (fr) 2007-06-14
TW200804239A (en) 2008-01-16
CN101365439A (zh) 2009-02-11
KR101396639B1 (ko) 2014-05-21
US8193242B2 (en) 2012-06-05
PT1959948E (pt) 2012-09-12
US20120296109A1 (en) 2012-11-22
JP5153641B2 (ja) 2013-02-27
NO20082768L (no) 2008-06-24
AU2006322051A1 (en) 2007-06-14
TWI403493B (zh) 2013-08-01
IL191937A (en) 2014-07-31
JP2009520690A (ja) 2009-05-28
EP1959948A2 (fr) 2008-08-27
US20070225366A1 (en) 2007-09-27
US7968597B2 (en) 2011-06-28
CY1113108T1 (el) 2016-04-13
IL191937A0 (en) 2009-08-03
US20090326067A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
IL191937A0 (en) Levodopa prodrug mesylate, compositions thereof and uses thereof
IL179438A0 (en) Levodopa prodrugs, and compositions and uses thereof
AP2436A (en) Immunogenic composition
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
GB0515052D0 (en) Organosiloxane compositions
IL183666A0 (en) Amide prodrug of gemcitabine, compositions and use thereof
EP1874345A4 (fr) Compositions immunostimulantes
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
GB0511319D0 (en) Polymeric compositions
GB0526038D0 (en) Immunogenic composition
ZA200710909B (en) Immunogenic composition
IL187732A0 (en) Levodopa compositions
ZA200707529B (en) Pro-fragrance and pro-flavorant compositions
GB2423081B (en) Pro-fragrance and pro-flavorant compositions
ZA200710854B (en) Immunogenic composition
GB0720489D0 (en) Novel mixtures, compositions and ususe
GB0516239D0 (en) Organosiloxane compositions
GB0524204D0 (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0526040D0 (en) Immunogenic composition
GB0526041D0 (en) Immunogenic composition